Ninlaro(ixazomib)
Ninlaro (ixazomib) is a small molecule pharmaceutical. Ixazomib was first approved as Ninlaro on 2015-11-20. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against proteasome subunit beta type-5. In addition, it is known to target proteasome subunit alpha type-7.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Ninlaro
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ixazomib citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NINLARO | Takeda | N-208462 RX | 2015-11-20 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ninlaro | New Drug Application | 2023-01-20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
HCPCS
No data
Clinical
Clinical Trials
150 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 5 | 3 | — | — | — | 7 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 5 | 1 | — | — | — | 5 | |
| Mantle-cell lymphoma | D020522 | C83.1 | 2 | 5 | — | — | — | 5 | |
| Immunoglobulin light-chain amyloidosis | D000075363 | 4 | 3 | — | — | — | 5 | ||
| Waldenstrom macroglobulinemia | D008258 | C88.0 | — | 4 | — | — | — | 4 | |
| Hematologic neoplasms | D019337 | 2 | 1 | — | — | — | 3 | ||
| Myeloid leukemia acute | D015470 | C92.0 | 2 | 1 | — | — | — | 3 | |
| Plasma cell leukemia | D007952 | C90.1 | 1 | 1 | — | — | — | 2 | |
| Plasmacytoma | D010954 | C90.3 | — | 2 | — | — | — | 2 | |
| Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 2 | — | — | — | 2 |
Show 33 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 6 | — | — | — | — | 6 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | 1 | — | — | — | — | 1 | ||
| Liposarcoma | D008080 | 1 | — | — | — | — | 1 | ||
| Alveolar soft part sarcoma | D018234 | 1 | — | — | — | — | 1 | ||
| Ewing sarcoma | D012512 | EFO_0000173 | 1 | — | — | — | — | 1 | |
| Neurofibrosarcoma | D018319 | 1 | — | — | — | — | 1 | ||
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | 1 | — | — | — | — | 1 | |
| Chronic progressive multiple sclerosis | D020528 | 1 | — | — | — | — | 1 | ||
| Glioblastoma | D005909 | EFO_0000515 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Progression-free survival | D000077982 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | IXAZOMIB |
| INN | ixazomib |
| Description | Ixazomib is a glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. It has a role as an apoptosis inducer, an orphan drug, a proteasome inhibitor, a drug metabolite and an antineoplastic agent. It is a member of benzamides, a dichlorobenzene, a glycine derivative and a member of boronic acids. |
| Classification | Small molecule |
| Drug class | proteozome inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O |
Identifiers
| PDB | 5LF7 |
| CAS-ID | 1072833-77-2 |
| RxCUI | 1723735 |
| ChEMBL ID | CHEMBL2141296 |
| ChEBI ID | — |
| PubChem CID | 25183872 |
| DrugBank | DB09570 |
| UNII ID | 71050168A2 (ChemIDplus, GSRS) |
Target
Agency Approved
PSMB5
PSMB5
Organism
Homo sapiens
Gene name
PSMB5
Gene synonyms
LMPX, MB1, X
NCBI Gene ID
Protein name
proteasome subunit beta type-5
Protein synonyms
Macropain epsilon chain, Multicatalytic endopeptidase complex epsilon chain, proteasome (prosome, macropain) subunit, beta type, 5, proteasome beta 5 subunit, proteasome catalytic subunit 3, Proteasome chain 6, Proteasome epsilon chain, proteasome subunit beta 5, Proteasome subunit MB1, Proteasome subunit X, proteasome subunit, beta type, 5, PSX large multifunctional protease X, testicular tissue protein Li 153
Uniprot ID
Mouse ortholog
Psmb5 (19173)
proteasome subunit beta type-5 (Q9R1P2)
Alternate
PSMA7
PSMA7
Organism
Homo sapiens
Gene name
PSMA7
Gene synonyms
HSPC
NCBI Gene ID
Protein name
proteasome subunit alpha type-7
Protein synonyms
epididymis secretory protein Li 276, proteasome (prosome, macropain) subunit, alpha type, 7, proteasome subunit alpha 4, proteasome subunit alpha 7, Proteasome subunit RC6-1, Proteasome subunit XAPC7, testicular tissue protein Li 151
Uniprot ID
Mouse ortholog
Psma7 (26444)
proteasome subunit alpha type-7 (Q9Z2U0)
Variants
Clinical Variant
No data
Financial
Ninlaro - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,689 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,663 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more